Poloxamer 188 failed to prevent exercise-induced membrane breakdown in mdx skeletal muscle fibers

Neuromuscul Disord. 2006 Dec;16(12):855-64. doi: 10.1016/j.nmd.2006.09.016. Epub 2006 Nov 21.

Abstract

We sought to determine the effectiveness of poloxamer 188 (P188) in protecting dystrophin-deficient, mdx skeletal muscle fiber membrane against exercise-induced breaches. mdx mice were treated with either P188 or placebo via intraperitoneal injections and run on a treadmill for 60-90 min. Membrane breakdown was quantified in cross-sections of rectus femoris muscle pretreated with Evans blue dye (in vivo). The mean % dye-penetrated muscle in the P188 and placebo groups was not significantly different in each of three trials. These results contrast with a recent report of P188 being highly effective in protecting the stretch- and dobutamine-stressed mdx heart muscle. The most likely explanations for the disparity are: (1) the exercise stress we used was beyond the protective range of P188, (2) P188 delivery and serum concentration were sub-optimal, or (3) the mdx skeletal myopathy and cardiomyopathy have fundamentally different responses to treatment.

MeSH terms

  • Animals
  • Cardiomyopathies / drug therapy
  • Cardiomyopathies / metabolism
  • Cardiomyopathies / physiopathology
  • Cell Membrane Permeability / drug effects*
  • Cell Membrane Permeability / physiology
  • Coloring Agents
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Administration Routes
  • Exercise Tolerance / drug effects
  • Exercise Tolerance / physiology
  • Female
  • Injections, Intraperitoneal
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Inbred mdx
  • Muscle Contraction / drug effects
  • Muscle Contraction / physiology
  • Muscle Fibers, Skeletal / drug effects*
  • Muscle Fibers, Skeletal / metabolism
  • Muscle Fibers, Skeletal / pathology
  • Muscle, Skeletal / drug effects*
  • Muscle, Skeletal / metabolism
  • Muscle, Skeletal / physiopathology
  • Muscular Dystrophy, Duchenne / drug therapy*
  • Muscular Dystrophy, Duchenne / metabolism
  • Muscular Dystrophy, Duchenne / physiopathology
  • Physical Conditioning, Animal / physiology
  • Poloxamer / pharmacology*
  • Poloxamer / therapeutic use
  • Sarcolemma / drug effects*
  • Sarcolemma / metabolism
  • Surface-Active Agents / pharmacology
  • Surface-Active Agents / therapeutic use
  • Treatment Failure

Substances

  • Coloring Agents
  • Surface-Active Agents
  • Poloxamer